Breaking News Instant updates and real-time market news.

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

07:45
07/23/19
07/23
07:45
07/23/19
07:45

Marinus Pharmaceuticals announces data from Phase 2 Amaryllis study

The Amaryllis Study enrolled patients with a baseline HAM-D17 score of 25.5 for the low dose group and 25.4 for the high dose group. In this open-label dose-optimization study, 25 patients received 675 mg of oral ganaxolone at dinner for 28 days and 43 patients received 675 mg of oral ganaxolone at dinner and bedtime for two days, followed by a dinner time dose of 1125 mg once daily for the remainder of the 28-day treatment regimen. The low dose showed a mean HAM-D17 reduction from baseline of 0.8, 9.8, and 12.2 at 24 hours of treatment at 14 and 28 days of treatment, respectively, and the high dose showed a mean HAM-D17 reduction of 2.7, 9.3 and 14.5 at 24 hours of treatment at 14 and 28 days of treatment, respectively. The high dose showed a HAMD-17 reduction at 24 hours of treatment that was 2.0 points greater than the low dose, which was generally sustained over the treatment regimen, suggesting an efficacy trend with early activity onset. Oral ganaxolone was generally safe and well-tolerated with no serious adverse events reported and no discontinuations due to treatment related adverse events. Data from the Amaryllis Study support continued use of the once daily 1125 mg oral dose in future clinical studies. The Company will continue to engage strategic interest in oral ganaxolone and believes that the Amaryllis data would potentially be the basis of a constructive partnership.

MRNS Marinus Pharmaceuticals
$3.99

0.11 (2.84%)

07/22/19
JEFF
07/22/19
NO CHANGE
Target $10
JEFF
Buy
Marinus could rally up to 50% on August depression data, says Jefferies
Jefferies analyst Andrew Tsai believes Marinus Pharmaceuticals could rally 25%-50% on the two Phase II postpartum depression datasets, expected by the middle of August. With the stock at $4 per share, the risk/reward favors the upside as the market appears to ascribe a low 15%-25% probability for PPD, Tsai tells investors in a research note. The analyst adds that his "stronger conviction" for positive data is supported by prior datasets and his doctor checks. He keeps a Buy rating on Marinus with a $10 price target.
03/05/19
JEFF
03/05/19
INITIATION
Target $10
JEFF
Buy
Marinus Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Andrew Tsai started Marinus Pharmaceuticals with a Buy rating and $10 price target. Marinus is an inexpensive name that offers a favorable setup at current price levels, Tsai tells investors in a research note. The stock's risk/reward for is "skewed heavily towards the upside" as the Street appears to underappreciate the company having multiple shots on goal, adds the analyst. He believes the Phase II postpartum depression readout in the first half of 2019 could rally stock up to 50% if positive.
02/27/19
MZHO
02/27/19
DOWNGRADE
Target $5
MZHO
Neutral
Marinus Pharmaceuticals downgraded to Neutral from Buy at Mizuho
Mizuho analyst Difei Yang downgraded Marinus Pharmaceuticals to Neutral and lowered her price target for the shares to $5 from $13. The stepping down of CEO Chris Cashman is "not good timing" as it comes in the middle of the "important" ongoing Phase II clinical trials of ganaxolone with data expected in the first half of 2019, Yang tells investors in a research note. The analyst sees the news as a negative development for Marinus and reduced her probability of success for ganaxolone in postpartum depression from 50% to 20%.
02/25/19
LEER
02/25/19
NO CHANGE
LEER
Outperform
Marinus clincal trial data supports MDD thesis, says SVB Leerink
SVB Leerink analyst Marc Goodman, in a note titled "Interesting Small MDD Data Set," noted to investors that last week data was posted on clinicaltrials.gov for an investigator-led study of oral ganaxolone as an add-on therapy in 10 postmenopausal women with treatment-resistant depression. While noting that it was unusual for a physician-driven study to see its results posted in this way, Goodman said the data further support his thesis that ganaxolone could work in the broader indication of major depressive disorder, or MDD. Though he said the study was "very small," he sees the data as "positive, though limited," Goodman tells investors. He keeps an Outperform rating on Marinus Pharmaceuticals shares.

TODAY'S FREE FLY STORIES

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$31.70

-2.48 (-7.26%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF falls -7.2% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$71.82

-6.26 (-8.02%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
Direxion Daily Jr Gld Mnrs Bull 3X Shrs falls -7.9% »

Direxion Daily Jr Gld…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$10.40

-3.9 (-27.27%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
PG&E falls -27.3% »

PG&E is down -27.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$198.05

18.785 (10.48%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
Estee Lauder rises 10.4% »

Estee Lauder is up 10.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

TGNA

Tegna

$16.42

1.34 (8.89%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
Tegna rises 9.4% »

Tegna is up 9.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

ARMK

Aramark

$41.24

4.17 (11.25%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
Aramark rises 11.2% »

Aramark is up 11.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$14.30

(0.00%)

09:43
08/19/19
08/19
09:43
08/19/19
09:43
Downgrade
PG&E rating change  »

PG&E downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$37.05

(0.00%)

, IQ

iQIYI

$17.08

(0.00%)

09:40
08/19/19
08/19
09:40
08/19/19
09:40
Options
Unusually active option classes on open August 19th »

Unusual total active…

WB

Weibo

$37.05

(0.00%)

IQ

iQIYI

$17.08

(0.00%)

LYFT

Lyft

$52.37

(0.00%)

XLU

Utilities SPDR

$61.35

(0.00%)

UAL

United Continental

$82.96

(0.00%)

WYNN

Wynn Resorts

$105.58

(0.00%)

EA

Electronic Arts

$89.56

(0.00%)

DB

Deutsche Bank

$6.95

(0.00%)

NVDA

Nvidia

$159.48

(0.00%)

MSFT

Microsoft

$136.13

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 10

    Sep

  • 23

    Sep

  • 27

    Oct

  • 13

    Nov

OMCL

Omnicell

$70.48

0.475 (0.68%)

09:38
08/19/19
08/19
09:38
08/19/19
09:38
Conference/Events
Omnicell management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

CHU

China Unicom

$9.93

0.155 (1.59%)

09:35
08/19/19
08/19
09:35
08/19/19
09:35
Downgrade
China Unicom rating change  »

China Unicom downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
08/19/19
08/19
09:35
08/19/19
09:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD pulled…

REDU

Rise Education

$7.88

-0.13 (-1.62%)

09:34
08/19/19
08/19
09:34
08/19/19
09:34
Downgrade
Rise Education rating change  »

Rise Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGNA

Tegna

$15.08

1.465 (10.76%)

09:31
08/19/19
08/19
09:31
08/19/19
09:31
Upgrade
Tegna rating change  »

Tegna upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

CLNC

Colony Credit Real Estate

$13.04

0.165 (1.28%)

09:31
08/19/19
08/19
09:31
08/19/19
09:31
Recommendations
Colony Credit Real Estate analyst commentary  »

Colony Credit Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$80.84

1.67 (2.11%)

09:30
08/19/19
08/19
09:30
08/19/19
09:30
Downgrade
Zscaler rating change  »

Zscaler downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 10

    Oct

  • 15

    Oct

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

, LGF.B

Lionsgate

$10.52

0.01 (0.10%)

09:30
08/19/19
08/19
09:30
08/19/19
09:30
Upgrade
Lionsgate, Lionsgate rating change  »

Lionsgate upgraded to…

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

LGF.B

Lionsgate

$10.52

0.01 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$199.26

-15.5 (-7.22%)

09:29
08/19/19
08/19
09:29
08/19/19
09:29
Recommendations
Palo Alto Networks analyst commentary  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 10

    Oct

  • 15

    Oct

PULM

Pulmatrix

$0.82

0.0076 (0.94%)

09:28
08/19/19
08/19
09:28
08/19/19
09:28
Hot Stocks
Pulmatrix receives U.S. patent covering iSPERSE formulations »

Pulmatrix has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

MMSI

Merit Medical

$36.17

-0.67 (-1.82%)

09:27
08/19/19
08/19
09:27
08/19/19
09:27
Hot Stocks
Merit Medical appoints Lynne Ward to board of directors »

Merit Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

VMW

VMware

$143.67

1.13 (0.79%)

, AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

09:27
08/19/19
08/19
09:27
08/19/19
09:27
Recommendations
VMware, Amazon.com, Microsoft analyst commentary  »

VMware to deliver…

VMW

VMware

$143.67

1.13 (0.79%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 04

    Sep

  • 10

    Sep

  • 10

    Oct

  • 27

    Oct

VCEL

Vericel

$16.31

0.705 (4.52%)

09:25
08/19/19
08/19
09:25
08/19/19
09:25
Conference/Events
Vericel participates in a conference call with SVB Leerink »

SVB Leerink to host a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

RNVA

Rennova Health

$0.00

(0.00%)

09:22
08/19/19
08/19
09:22
08/19/19
09:22
Hot Stocks
Rennova receives CMS notice on change in ownership for Jellico Medical Center »

Rennova Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$199.26

-15.5 (-7.22%)

09:20
08/19/19
08/19
09:20
08/19/19
09:20
Recommendations
Palo Alto Networks analyst commentary  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 10

    Oct

  • 15

    Oct

HZNP

Horizon Pharma

$27.00

0.17 (0.63%)

09:19
08/19/19
08/19
09:19
08/19/19
09:19
Hot Stocks
AJO review says Horizon Pharma's teprotumumab could potentially treat TED »

An evaluation of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 18

    Sep

NXRT

NexPoint Residential

$44.85

0.9 (2.05%)

09:19
08/19/19
08/19
09:19
08/19/19
09:19
Recommendations
NexPoint Residential analyst commentary  »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.